For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What are the growth projections for the amebiasis market from 2024 to 2029?
The amebiasis market size has grown strongly in recent years. It will grow from $0.82 billion in 2024 to $0.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing incidence of amoebic infections in tropical regions, poor sanitation and hygiene practices in developing countries, increasing international travel, especially to endemic areas, growing awareness about the disease, and lack of access to clean drinking water in rural areas.
The amebiasis market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to rising prevalence of immune-compromised populations, increasing government initiatives to improve sanitation and healthcare infrastructure, growing investments in research for new treatments, increasing focus on health initiatives to combat parasitic diseases, and growing demand for effective oral medications. Major trends in the forecast period include growing adoption of combination therapies, development of vaccines, advancements in drug delivery systems, advancements in pharmaceutical research, and development of novel antiprotozoal drugs.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21094&type=smp
What strategic initiatives by market players are driving amebiasis industry growth?
The escalating cases of parasitic infections are expected to propel the growth of the amebiasis market going forward. Parasitic infections refer to diseases caused by parasites such as protozoa, helminths, or ectoparasites that live on or inside a host and derive nutrients at the host’s expense. The escalating cases of parasitic infections are attributed to factors such as increased travel, climate change, poor sanitation, and the rise of drug resistance, which collectively contribute to the spread and persistence of these infections. Amebiasis, caused by the entamoeba histolytica parasite, contributes to parasitic infections by invading the intestines, leading to symptoms such as diarrhea, abdominal pain, and potentially more severe complications such as tissue damage and liver abscesses. For instance, in January 2024, according to the Animal and Plant Health Agency, a UK-based government agency, a total of 1,071 diagnoses of Parasitic Gastroenteritis (PGE) were recorded in 2022, including 190 cases of haemonchosis and 95 cases of nematodirosis. The number of haemonchosis cases in 2022 was relatively high compared to the previous year. Therefore, the escalating cases of parasitic infections are driving the growth of the amebiasis market.
Impact Of Poor Sanitation On The Growth Of The Market
The increasing prevalence of poor sanitation is expected to propel the growth of the amebiasis market going forward. Poor sanitation refers to the lack of access to clean water, proper sewage disposal, and hygienic facilities, which can lead to the spread of diseases. The increasing prevalence of poor sanitation is attributed to factors such as inadequate infrastructure, lack of proper waste management systems, and rapid urbanization. Amebiasis thrives in conditions of poor sanitation, as contaminated water and food sources provide a breeding ground for the Entamoeba histolytica parasite, which can spread rapidly in environments lacking proper hygiene and waste management. For instance, in July 2023, according to the United Nations Water, a US-based government agency, in 2022, 2 billion people still did not have access to basic hygiene services, while 3.5 billion lacked safely managed sanitation. Therefore, the increasing prevalence of poor sanitation is driving the growth of the amebiasis market.
What emerging segments are shaping the future landscape of the amebiasis industry?
The amebiasis market covered in this report is segmented –
1) By Type: Metronidazole, Paromomycin, Tinidazole
2) By Route Of Administration: Oral, Intravenous
3) By Application: Hospital, Pharmacy
Subsegments:
1) By Metronidazole: Oral Metronidazole, Intravenous Metronidazole, Combination Therapy with Metronidazole
2) By Paromomycin: Oral Paromomycin, Paromomycin in Combination with Other Drugs
3) By Tinidazole: Oral Tinidazole, Tinidazole for Severe Infections
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/amebiasis-global-market-report
Which sustainability trends are emerging in the amebiasis market?
Major companies operating in the amebiasis market are focusing on developing advanced solutions, such as ready-to-use oral liquid metronidazole, to improve patient compliance and treatment efficacy. Ready-to-use oral liquid metronidazole is a pre-prepared liquid form of the antibiotic used to treat infections like amebiasis, making it easier for patients who have trouble swallowing pills. For instance, in November 2023, Kesin Pharma Corporation, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Likmez (metronidazole) oral suspension, 500 mg/5 mL, marking it as the first ready-to-use oral liquid formulation of metronidazole. The oral suspension formulation provides a pediatric-friendly option, making it easier for children to take the medication with accurate dosing, ensuring better adherence to treatment protocols. The liquid form offers flexibility in dosing, allowing healthcare providers to adjust treatment based on individual patient needs, particularly for varying infection severity.
How are key players in the amebiasis market strengthening their market position?
Major companies operating in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., Zydus Lifesciences Limited
Which geographic areas are contributing significantly to the growth of the amebiasis sector?
North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the amebiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Amebiasis Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21094
Need Customized Data On Amebiasis Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=21094&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
